Know Cancer

or
forgot password

Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors


Phase 2
18 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors


- In this study, participants will be divided into two groups. One group will undergo
intensive lifestyle changes (Lifestyle Intervention Group) designed by the Diabetes
Prevention Group, and the other (Control Group) will follow the guidelines for healthy
living established by the Food Guide Pyramid and the National Cholesterol Education
Program.

- All visits will take place at the General Clinical Research Center at the Massachusetts
General Hospital.

- At the initial visit, the following will be performed: Bionutrition evaluation; Oral
Glucose Tolerance Test (OGTT); additional blood work and; Dual Energy X-Ray
Absorptiometry (DXA) Scan.

- After the initial visit, visits will be scheduled at 3, 6 and 12 months after and the
above procedures will be repeated.

- Participants will be randomized into one of the two study groups. Lifestyle
Intervention Group: The goal for participants assigned to this group are to achieve
and maintain a weight loss of at least 7% of initial body weight through a healthy low
calorie, low fat diet and to engage in physical activity of moderate intensity.
Control Group: participants in this group will receive standard nutrition and exercise
recommendations from the Food Guide Pyramid and the National Cholesterol Education
Program Step 1 diet to reduce body weight and increase physical activity.


Inclusion Criteria:



- Histologically confirmed prostate cancer

- Current Hormone therapy with GnRH agonist of 3 months or longer

- Overweight or obese (body mass index of 25kg/m2 or greater)

- No other conditions that prevent intensive lifestyle intervention

Exclusion Criteria:

- History of diabetes mellitus requiring drug therapy

- Hemoglobin Aic of 7% or greater

- Symptomatic metastatic disease

- Myocardial infarction within 6 months

- Treatment with anabolic agents or metabolic agents known to affect insulin or glucose
levels

- Disease progression according to PSA Working Group Criteria

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Matthew Smith, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital

Authority:

United States: Institutional Review Board

Study ID:

07-081

NCT ID:

NCT00738140

Start Date:

September 2007

Completion Date:

September 2012

Related Keywords:

  • Prostate Cancer
  • insulin sensitivity
  • Diabetes Prevention Program
  • lifestyle intervention
  • Prostatic Neoplasms
  • Insulin Resistance

Name

Location

Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617